Kymera Therapeutics (KYMR) Equity Average (2019 - 2025)
Historic Equity Average for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $958.9 million.
- Kymera Therapeutics' Equity Average rose 2154.09% to $958.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $958.9 million, marking a year-over-year increase of 2154.09%. This contributed to the annual value of $615.3 million for FY2024, which is 3903.06% up from last year.
- As of Q3 2025, Kymera Therapeutics' Equity Average stood at $958.9 million, which was up 2154.09% from $878.9 million recorded in Q2 2025.
- Kymera Therapeutics' Equity Average's 5-year high stood at $958.9 million during Q3 2025, with a 5-year trough of $266.7 million in Q2 2021.
- Over the past 5 years, Kymera Therapeutics' median Equity Average value was $471.4 million (recorded in 2021), while the average stood at $552.2 million.
- Per our database at Business Quant, Kymera Therapeutics' Equity Average soared by 43240.49% in 2021 and then plummeted by 2118.87% in 2023.
- Over the past 5 years, Kymera Therapeutics' Equity Average (Quarter) stood at $471.4 million in 2021, then grew by 6.39% to $501.5 million in 2022, then fell by 21.19% to $395.3 million in 2023, then surged by 118.66% to $864.3 million in 2024, then grew by 10.94% to $958.9 million in 2025.
- Its Equity Average stands at $958.9 million for Q3 2025, versus $878.9 million for Q2 2025 and $810.9 million for Q1 2025.